Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 50Carcinoma, Non-Small-Cell Lung 26Squamous Cell Carcinoma of Head and Neck 25Head and Neck Neoplasms 12Neoplasm Metastasis 11Neoplasms 10Colonic Neoplasms 10Rectal Neoplasms 9Pancreatic Neoplasms 9Lung Neoplasms 9Mouth Neoplasms 6Carcinoma, Squamous Cell 6Carcinoma 6Laryngeal Neoplasms 5Hypopharyngeal Neoplasms 5Oropharyngeal Neoplasms 4Thyroid Neoplasms 3Solid Tumors 3Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Pancreatic Ductal 3Breast Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Laryngeal Diseases 2mCRC 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

fludarabine 4Cyclophosphamide 4fludarabine phosphate 3Melphalan 3pembrolizumab 2obinutuzumab 2blinatumomab 2Rituximab 2Radiotherapy 2Lenalidomide 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1sacituzumab govitecan 1palbociclib 1nilotinib 1isatuximab 1avelumab 1atezolizumab 1acalabrutinib 1Whole-Body Irradiation 1Trastuzumab 1Sirolimus 1Neoadjuvant Therapy 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Cetuximab × 90 days × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡